Odyssey Therapeutics, Inc. (ODTX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Odyssey Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Regan O'Neill Burkehill Global Management LP | 20,000 | $374,200 | $344,800 | -$29,400 | -7.86% |
 Olga Maltseva Catalio Capital Management LP | 457,839 | $8.57M | $7.92M | -$645,553.31 | -7.54% |
 Raymond Debbane Siren, L.L.C. | 200,000 | $3.74M | $3.51M | -$228,000 | -6.09% |
Odyssey Therapeutics, Inc. (ODTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Odyssey Therapeutics, Inc. ever had a stock split?
Odyssey Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gary D. Glick CEO | NASDAQ (CM) Exchange | 67613T104 CUSIP |
| US Country | 100 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines aimed at treating autoimmune and inflammatory diseases. The company is at the forefront of research and development with a diverse pipeline of therapeutic candidates targeting various aspects of immune response. Established in 2021 and based in Boston, Massachusetts, Odyssey Therapeutics is committed to delivering effective solutions for patients suffering from complex diseases by harnessing advanced biopharmaceutical technologies.
Products and Services
- OD-001:
An oral small molecule inhibitor of receptor-interacting protein kinase 2 (RIPK2) currently undergoing a phase 2a clinical trial for the treatment of ulcerative colitis. This therapy aims to diminish inflammation and promote healing in patients suffering from this debilitating condition.
- OD-002:
This treatment is an oral small molecule SLC15A4 inhibitor designed to effectively block TLR7/8/9-mediated activation of pathogenic inflammatory responses via interferon regulatory factor 5 (IRF5). This unique mechanism is intended to reduce the severity and frequency of autoimmune flare-ups.
- OD-003:
A protein therapeutic intended to selectively activate tumor necrosis factor receptor 2 (TNFR2) on regulatory T cells (Treg). This novel therapeutic approach aims to enhance the body's natural immune regulation, thereby potentially ameliorating autoimmune diseases.
- TSLP/IL-33 Bispecific Antagonist:
This product targets both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-33 (IL-33), which are key cytokines involved in allergic responses and inflammation. By antagonizing these pathways, the bispecific antagonist may offer a new strategy for treating relevant conditions like asthma and eczema.
- Oral Small Molecule IL-1 Receptor-Associated Kinase 4 (IRAK4) Scaffolding Inhibitor:
Designed to inhibit IRAK4 signaling, this oral small molecule aims to disrupt the inflammatory signaling cascade that contributes to various autoimmune diseases, providing a potential therapeutic option for managing chronic inflammation.
- Small Molecule Inhibitor of IRF5:
This investigational product specifically targets IRF5, a critical mediator in inflammatory pathways. By inhibiting IRF5, this small molecule seeks to moderate immune responses and mitigate the impact of autoimmune conditions on patients' health.
Contact Information
